 Pulmonary hypertension has been described in sarcoidosis. It can be a significant problem, not responsive to treatment with anti-inflammatory drugs for the sarcoidosis 1;2. Inhaled iloprost has been approved for treatment of pulmonary hypertension 3. We propose to study the effectiveness of inhaled iloprost for sarcoidosis associated pulmonary hypertension SAPAH. This is an open label trial, with patients receiving 16 weeks of therapy. Clinical and hemodynamic outcome of therapy will be assessed. 